This proof of concept was first shown with the STMN2 cryptic exon in post-mortem frontal cortex samples, in which its presence was able to discriminate between patients with FTD-TDP, progressive supranuclear palsy, and healthy control participants [31]. This evidence concerns the gene STMN2 and frontotemporal dementia.